Advertisement

Topics

WuXi AppTec Company Profile

19:54 EST 17th November 2017 | BioPortfolio

WuXi AppTec’s U.S. Manufacturing and Testing group provides a comprehensive range of integrated programs for biologics, advanced therapies and medical devices – along with expert technical and regulatory guidance – to help take products from preclinical development to commercialization and beyond. Facilities – located in Philadelphia, St. Paul and Atlanta – are FDA registered and ISO certified with experienced scientists dedicated to meeting the unique needs of our clients. Testing services utilize cutting-edge in vitro, in vivo, molecular and analytical methodologies to meet the requirements of global regulatory agencies. Flexible, high-capacity cGMP manufacturing is offered for cell therapies, gene therapies, and gene-mediated cell therapies.


News Articles [87 Associated News Articles listed on BioPortfolio]

WuXi AppTec acquires ResearchPoint Global

WuXi AppTec, a global pharmaceutical, biotechnology and medical device open-access capability and technology platform, has acquired ResearchPoint Global (RPG), a U.S.-based CRO with expertise spanning...

Wuxi AppTec says expanded STA will get drugs to market faster

Wuxi AppTec says merged development services and API business will provide customers with more integrated service. 

M&As this week: WuXi AppTec, Cachet Pharmaceutical, Shenzhen Neptunus Bioengineering

Chinese pharmaceutical company WuXi AppTec plans to acquire US-based contract research organisation (CRO) ResearchPoint Global (RPG).

WuXi AppTec acquires US-based CRO noting recent Chinese regulatory reforms

WuXi AppTecâs acquisition of ResearchPoint Global (RPG) follows the release of a new guideline that will enable Chinese companies to accept clinical trial data from other countries.

WuXi AppTec acquires US-based CRO ResearchPoint Global

WuXi AppTecâs acquisition of ResearchPoint Global (RPG) follows the release of a new guideline that will enable Chinese companies to accept clinical trial data from other countries.

WuXi AppTec report shows prospects of immunotherapy treatments for cancer

China-based company WuXi AppTec has published a new report highlighting the prospects of immunotherapy as a potential treatment for cancer.

WuXi’s Pharmaceutical Development Services Division, STA merge

STA Pharmaceutical, a WuXi AppTec group company and an open-access capability and technology platform for small molecule pharmaceutical development and manufacturing—announces that it has merged wit...

WuXi NextCODE, a Genomics CRO, Closes $240 Million Series B Round

WuXi NextCODE completed a Series B fundraising with $240 million in new capital for its genomics CRO operations. In May, the company closed the first tranche of the round. NextCODE is WuXi AppTec's pl...

PubMed Articles [2 Associated PubMed Articles listed on BioPortfolio]

Ownership reform and the changing manufacturing landscape in Chinese cities: The case of Wuxi.

Since the economic transition, manufacturing in China has undergone profound changes not only in number of enterprises, but also in ownership structure and intra-urban spatial distribution. Investigat...

Contamination characteristics and source apportionment of methylated PAHs in agricultural soils from Yangtze River Delta, China.

Alkylated PAHs (APAHs) have been shown to be more toxic and persistent than their non-alkylated parent compounds. However, little is known about the extent of soil contamination by these pollutants. T...

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Serological Screening of Gastric Cancer in Wuxi Region

The purpose of this study is to determine whether detection of pepsinogen Ⅰand Ⅱ combined with Helicobacter pylori antibody, so-called ABC method , is fit on gastric cancer screening i...

Companies [13 Associated Companies listed on BioPortfolio]

WuXi PharmaTech (Cayman) Inc.

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused co...

WuXi AppTec

WuXi AppTec’s U.S. Manufacturing and Testing group provides a comprehensive range of integrated programs for biologics, advanced therapies and medical devices – along wi...

WuXi PharmaTech, Ltd.

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused com...

Wuxi Syder Bio-products Co.,Ltd.

Wuxi Syder Bio-Products Co., LTD is a specialized one mainly producing Heat Stable a-Amylase. They devote themselves to making a breakthough in fermentation level, products quality and using effects. ...

WuXi PharmaTech

Founded in 2001 and located in WaiGaoQiao Free Trade Zone, Shanghai, WuXi PharmaTech is a research service company that provides services to support new drug discovery and the chemical development of ...

More Information about "WuXi AppTec" on BioPortfolio

We have published hundreds of WuXi AppTec news stories on BioPortfolio along with dozens of WuXi AppTec Clinical Trials and PubMed Articles about WuXi AppTec for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of WuXi AppTec Companies in our database. You can also find out about relevant WuXi AppTec Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record